Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2045

Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.

Patents
1,566

Quick answer

1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12215322

    Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12214014

    Methods for scar reduction by converting scar fibroblasts into adipocytes with hair follicle-derived signals

    The Regents of the University of California · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12213964

    Isoxazoline parasiticide formulations

    Tarsus Pharmaceuticals, Inc. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2025027551

    VACCIN ANTI-IBV AVEC PROTÉINE DE SPICULE DE DMV/1639 HÉTÉROLOGUE

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Thu Feb 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. WO 2025030001

    PROCÉDÉS ET COMPOSITIONS POUR LE MAINTIEN DE LA MOBILITÉ ET/OU DE LA MASSE DES MUSCLES SQUELETTIQUES, ET/OU POUR LA RÉCUPÉRATION DE LA FORCE DES MUSCLES SQUELETTIQUES

    ABBOTT LAB [US] · Granted Thu Feb 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2025027051

    INHIBITEURS DE SPHINGOSINE-1-PHOSPHATE LYASE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES

    AB SCIENCE [FR] · Granted Thu Feb 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12220421

    Inhibitors of C. difficile spore germination

    THE BOARDS OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12221460

    Antibody drug conjugates

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12220415

    WEE1 kinase inhibitors and methods of treating cancer using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12221627

    Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12220446

    Use of upstream open reading frame 45aa-uORF nucleotide sequence of PTEN gene and polypeptide coded by 45aa-uORF

    THE FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12221462

    Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells

    Allogene Therapeutics, Inc. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12220424

    Compositions comprising nicotinamide riboside and a urolithin

    Amazentis SA · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12221622

    Modified pluripotent cells

    The Regents of the University of California · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12220409

    Roflumilast formulations with an improved pharmacokinetic profile

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12220485

    Method of making lipid-encapsulated RNA nanoparticles

    ARCTURUS THERAPEUTICS, INC. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12220455

    Coronavirus vaccine compositions and methods

    ARCTURUS THERAPEUTICS, INC. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12223643

    Machine-learning system for diagnosing disorders and diseases and determining drug responsiveness

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12221422

    Compounds and their use for the treatment of alpha1-antitrypsin deficiency

    CENTESSA PHARMACEUTICALS (UK) LIMITED · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12220453

    Compositions and treatments for Haemophilus influenzae

    The Board of Regents of the University of Oklahoma · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12220389

    Combination therapy for the treatment of tinnitus and other medical conditions

    The Regents of the University of California · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12221607

    Multi-targeted single entity conjugates

    Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12221610

    RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12221463

    Method of promoting wound healing by inhibiting CCR3

    The Board of Regents of the University of Oklahoma · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12222355

    Therapeutic antibodies against ROR-1 protein and methods for use of same

    The Regents of the University of California · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12220447

    Proteolytic enzyme composition

    Bright Lifecare PVT LTD. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12220420

    Combination therapy for cancer treatment

    Galera Labs, LLC · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12221491

    PSMD9 inhibitors for the treatment of hepatic lipid dysregulation

    The Regents of the University of California · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12220595

    Stem cell rich plasma compositions and uses thereof for treating aging subjects

    Advanced Neuroregenerative Therapies, LLC. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12221414

    Quaternary ammonium salt compound, preparation method therefor and use thereof

    WEST CHINA HOSPITAL, SICHUAN UNIVERSITY · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12221452

    Synthesis of cantharidin

    Verrica Pharmaceuticals Inc. · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12221483

    Fusion protein and nucleic acid encoding sequence thereof, and uses of the same

    China Medical University Hospital · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12221441

    Plasma kallikrein inhibitors and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12221612

    Plants having increased oil quality

    Regents of the University of Minnesota · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12221629

    Methods for producing fibroadipogenic progenitor cells

    Regents of the University of Minnesota · Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 2025049789

    METHODS OF TREATING ALOPECIA ARAETA

    ABBVIE INC [US] · Granted Thu Feb 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12226491

    Nano-satellite complexes

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12227763

    Methods and compositions for treating cancer

    CRISPR THERAPEUTICS AG · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12227482

    Compounds and compositions for the treatment of cancer

    The Regents of the University of California · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12226474

    Methods and compositions for treating infections

    Decoy Therapeutics Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12226455

    Medical composition for treating cardiac wasting and cachexia

    RELAXERA PHARMAZEUTISCHE GMBH & CO. KG · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12227508

    TGF-β inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12230364

    Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12227503

    Compositions and methods for modulating hair growth

    The Regents of the University of California · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12227584

    Multivalent and multispecific OX40-binding fusion proteins

    Inhibrx Biosciences, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12228572

    Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells

    The First Hospital of China Medical University · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12230378

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12227744

    Compositions and methods for inhibiting expression of transthyretin

    Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2045?

1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.